Key Takeaways Expansion in Norway and obtaining EU approvals bolster revenue potential and support Moberg Pharma's European growth strategy. Retaining full rights to MOB-015 improves margins and control over commercialization, with supply chain enhancements ensuring stable product availability.Read more
Moberg Pharma AB (publ), a pharmaceutical company, develops and commercializes medical products primarily in Sweden. It offers MOB-015 for the treatment of nail fungus under the Terclara brand. The company was formerly known as Moberg Derma AB (publ) and changed its name to Moberg Pharma AB (publ) in May 2013. Moberg Pharma AB (publ) was incorporated in 2006 and is based in Bromma, Sweden.
